专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007008712A3 ANTI-ALPHA V BETA 6 ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：抗αVβ6抗体及其用途
公开(公告)号：WO2007008712A3
公开(公告)日：2007-08-02
申请号：PCT/US2006026598
申请日：2006-07-10
申请人： BIOGEN IDEC INC , VIOLETTE SHELIA , KOOPMAN LOUISE A , SIMON KENNETH J , WEINREB PAUL H , VAN VLIJMEN HERMAN , SALDANHA JOSE , LUGOVSKOY ALEXEY A
发明人： VIOLETTE SHELIA , KOOPMAN LOUISE A , SIMON KENNETH J , WEINREB PAUL H , VAN VLIJMEN HERMAN , SALDANHA JOSE , LUGOVSKOY ALEXEY A
IPC分类号： C12P21/08 , A61K39/395 , C07H21/04 , C07K16/00 , C12P21/04 , G01N33/53 , G01N33/574
CPC分类号： C07K16/2839 , A61K2039/505 , A61K2039/545 , C07K16/30 , C07K2317/24 , C07K2317/41 , C07K2317/567 , C07K2317/76 , C07K2317/77 , G01N33/57407 , G01N33/57492 , G01N33/6893 , G01N2333/70546 , G01N2800/085 , G01N2800/12 , G01N2800/20 , G01N2800/347 , Y10S424/80 , Y10S424/801
摘要： The present invention is in the fields of cell biology, immunology and oncology. Specifically, the invention relates to humanized antibodies that recognizes v 6 integrins which comprises a variable region of nonhuman origin and at least -a portion of an immunoglobulin of human origin. The invention also relates to processes for their preparation, to pharmaceutical compositions comprising them and to methods of treating various diseases by administering humanized anti- v 6 antibodies. The invention also relates to the identification of differential expression of the integrin avß6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin avß6.
摘要翻译：本发明属于细胞生物学，免疫学和肿瘤学领域。具体而言，本发明涉及识别v6整联蛋白的人源化抗体，其包含非人源可变区和至少一部分人源免疫球蛋白。本发明还涉及其制备方法，包含它们的药物组合物以及通过施用人源化抗v6抗体来治疗各种疾病的方法。本发明还涉及鉴定肿瘤细胞和组织表面上的整联蛋白αvβ6的差异表达，使用这种差异表达来确定肿瘤细胞的转移潜能，以及诊断和治疗/预防肿瘤转移的方法和用于使用配体，特别是与整联蛋白αvβ6结合的抗体消除残留的转移性肿瘤细胞。

2. 发明申请

WO2003100033A2 ANTI-αvβ6 ANTIBODIES 审中-公开
标题翻译：抗甲状腺炎抗体
公开(公告)号：WO2003100033A2
公开(公告)日：2003-12-04
申请号：PCT/US2003/008048
申请日：2003-03-13
申请人： BIOGEN, INC. , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , VIOLETTE, Shelia, M. , WEINREB, Paul, H. , SIMON, Kenneth, J. , SHEPPARD, Dean , LEONE, Diane, R.
发明人： VIOLETTE, Shelia, M. , WEINREB, Paul, H. , SIMON, Kenneth, J. , SHEPPARD, Dean , LEONE, Diane, R.
IPC分类号： C12N
CPC分类号： C07K16/2839 , A61K47/48507 , A61K47/48561 , A61K47/48623 , A61K47/68 , A61K47/6835 , A61K47/6849 , A61K47/6851 , A61K47/6865 , A61K51/1027 , A61K51/1066 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57492 , G01N33/6893 , G01N2333/70546 , G01N2800/085 , G01N2800/205
摘要： Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose %Qmediated diseases.
摘要翻译：特异性结合M.96的单克隆抗体。还包括使用这些抗体治疗具有或具有006介导的疾病的风险的哺乳动物或诊断％Q介导的疾病的方法。

3. 发明申请

WO2006096653A3 METHODS OF HUMANIZING IMMUNOGLOBULIN VARIABLE REGIONS THROUGH RATIONAL MODIFICATION OF COMPLEMENTARITY DETERMINING RESIDUES 审中-公开
标题翻译：通过修复残留量的相关性修饰免疫球蛋白变异区域的方法
公开(公告)号：WO2006096653A3
公开(公告)日：2007-07-12
申请号：PCT/US2006007955
申请日：2006-03-06
申请人： BIOGEN IDEC INC , LUGOVSKOY ALEXEY ALEXANDROVICH , HANF KARL , LI YOU , SIMON KENNETH , VAN VLIJMEN HERMAN
发明人： LUGOVSKOY ALEXEY ALEXANDROVICH , HANF KARL , LI YOU , SIMON KENNETH , VAN VLIJMEN HERMAN
IPC分类号： C07K16/00
CPC分类号： C07K1/00 , C07K16/00 , C07K16/2842 , C07K16/30 , C07K16/465 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/92
摘要： The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.
摘要翻译：本发明至少部分地基于以下发现，即可以使用非人供体抗体CDR残基的战略修饰来使抗体人源化。这样的修饰调节供体抗体CDR和包含CDR移植抗体的可变结构域的人受体抗体框架区之间的3D结构拟合。而现有技术的人源化方法依赖于进行框架取代（其中所选择的人类框架残基反向到存在于非人供体抗体中的相应氨基酸残基），本发明至少部分地基于人源化抗体的方法，其中选择的CDR残基和任选相邻的FR残基被改变以适应供体和受体抗体之间的FR氨基酸序列的差异。

4. 发明申请

WO2004002431A3 HUMANIZED ANTI-LYMPHOTOYIN BETA RECEPTOR ANTIBODIES 审中-公开
标题翻译：人源化抗淋巴因子β受体抗体
公开(公告)号：WO2004002431A3
公开(公告)日：2004-08-26
申请号：PCT/US0320762
申请日：2003-07-01
申请人： BIOGEN INC , GARBER ELLEN , SIMON KENNETH , SALDANHA JOSE
发明人： GARBER ELLEN , SIMON KENNETH , SALDANHA JOSE
IPC分类号： C12N15/09 , A61K39/395 , A61P35/00 , C07K16/28 , C07K16/46 , C07K17/08 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/02 , C07H21/04 , C07K16/00 , C12N5/12
CPC分类号： C07K16/2875 , A61K2039/505 , C07K2317/24 , C07K2317/565
摘要： This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-beta-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.
摘要翻译：本发明涉及对淋巴毒素β受体（LT-β-R）特异性的人源化抗体，产生这些抗体的细胞系，由该抗体制备的免疫化学物，以及使用该抗体的诊断方法。本发明还涉及单独或与化学治疗剂组合的抗体在治疗方法中的用途。

5. 发明申请

WO2011085369A1 ASSAY FOR JC VIRUS ANTIBODIES 审中-公开
标题翻译：测试JC病毒抗体
公开(公告)号：WO2011085369A1
公开(公告)日：2011-07-14
申请号：PCT/US2011/020832
申请日：2011-01-11
申请人： BIOGEN IDEC MA INC. , GORELIK, Leonid , SIMON, Kenneth, J. , SUBRAMANYAM, Meena , RUSHE, Mia, Marie
发明人： GORELIK, Leonid , SIMON, Kenneth, J. , SUBRAMANYAM, Meena , RUSHE, Mia, Marie
IPC分类号： C12Q1/70 , C12N15/86
CPC分类号： G01N33/56983 , G01N2333/025 , G01N2469/20 , G01N2800/50
摘要： The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.
摘要翻译：本公开涉及用于分析样品存在JC病毒抗体的方法和试剂。公开了一种方法，其包括从受试者（例如血浆，血清，血液，尿液或脑脊液）获得生物样品，在适合于JCV结合的条件下使样品与高度纯化的病毒样颗粒（HPVLP）接触样品中的抗体与HPVLP的检测，并检测JCV抗体在样品中与HPVLP结合的水平。在一个实施方案中，确定受试样品中抗JCV抗体的水平提供了鉴定受试者中PML风险的方法。

6. 发明申请

WO2007008712A8 ANTI-ALPHA V BETA 6 ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2007008712A8
公开(公告)日：2007-11-01
申请号：PCT/US2006026598
申请日：2006-07-10
申请人： BIOGEN IDEC INC , VIOLETTE SHELIA , KOOPMAN LOUISE A , SIMON KENNETH J , WEINREB PAUL H , VAN VLIJMEN HERMAN , SALDANHA JOSE , LUGOVSKOY ALEXEY A
发明人： VIOLETTE SHELIA , KOOPMAN LOUISE A , SIMON KENNETH J , WEINREB PAUL H , VAN VLIJMEN HERMAN , SALDANHA JOSE , LUGOVSKOY ALEXEY A
IPC分类号： C12P21/08 , A61K39/395 , C07H21/04 , C07K16/00 , C12P21/04 , G01N33/53 , G01N33/574
CPC分类号： C07K16/2839 , A61K2039/505 , A61K2039/545 , C07K16/30 , C07K2317/24 , C07K2317/41 , C07K2317/567 , C07K2317/76 , C07K2317/77 , G01N33/57407 , G01N33/57492 , G01N33/6893 , G01N2333/70546 , G01N2800/085 , G01N2800/12 , G01N2800/20 , G01N2800/347 , Y10S424/80 , Y10S424/801
摘要： The present invention is in the fields of cell biology, immunology and oncology. Specifically, the invention relates to humanized antibodies that recognizes v 6 integrins which comprises a variable region of nonhuman origin and at least -a portion of an immunoglobulin of human origin. The invention also relates to processes for their preparation, to pharmaceutical compositions comprising them and to methods of treating various diseases by administering humanized anti- v 6 antibodies. The invention also relates to the identification of differential expression of the integrin avß6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin avß6.

7. 发明申请

WO2007068872A1 REMOVABLE WASTE CONTAINER FOR A SINK 审中-公开
标题翻译：可拆卸的垃圾容器
公开(公告)号：WO2007068872A1
公开(公告)日：2007-06-21
申请号：PCT/GB2006/004085
申请日：2006-11-01
申请人： KNOWLES, Simon, Kenneth, Guy , CALABRESE, Salvatore, Antonio
发明人： KNOWLES, Simon, Kenneth, Guy , CALABRESE, Salvatore, Antonio
IPC分类号： E03C1/266
CPC分类号： E03C1/266
摘要： A sink unit comprises a sink element (14) having a waste outlet (24) in communication with a drain inlet (30), and a removable waste container (16) for collecting solid waste and which is positionable beneath the sink element (14) and interposable between the waste outlet (24) of the sink element (14) and the drain inlet (30). The removable waste container (16) includes a solid base (44), a solid wall or walls (46), a waste inlet (48) which, when the container (16) is positioned beneath the sink element (14), is in communication with the waste outlet (24) of the sink element (14), and a waste liquid outlet (52) which is formed in the base and which is in fluid communication with the drain inlet (30). In use and with the removable waste container' (16) positioned beneath the sink element (14), liquid and solid waste moves from the sink element (14) to the removable waste container (16) and the liquid waste then drains through the waste liquid outlet to the drain inlet (30) leaving the solid waste in the container (16), and with the container (16) removed, liquid and solid waste moves from the sink element (14) to the drain inlet (30) without passing through the container (16).
摘要翻译：水槽单元包括具有与排水入口（30）连通的废物出口（24）的水槽元件（14）和用于收集固体废物的可移除废物容器（16），其可定位在水槽元件（14）下方，并且在宿元件（14）的废液出口（24）和排水入口（30）之间可以插入。可移除废物容器（16）包括固体基部（44），实心壁或壁（46），废物入口（48），当容器（16）位于吸收元件（14）下方时，废物入口与沉没元件（14）的废物出口（24）的连通以及形成在基部中并与排水入口（30）流体连通的废液出口（52）。在使用中，并且与位于下沉元件（14）下方的可移除废物容器（16）一起，液体和固体废物从沉没元件（14）移动到可移除的废物容器（16），然后废液通过废物排出液体出口到排放入口（30），将固体废物留在容器（16）中，并且随着容器（16）被移除，液体和固体废物从沉没元件（14）移动到排水入口（30）而不经过通过容器（16）。

8. 发明申请

WO2006096653A2 METHODS OF HUMANIZING IMMUNOGLOBULIN VARIABLE REGIONS THROUGH RATIONAL MODIFICATION OF COMPLEMENTARITY DETERMINING RESIDUES 审中-公开
标题翻译：通过修复残留量的相关性修饰免疫球蛋白变异区域的方法
公开(公告)号：WO2006096653A2
公开(公告)日：2006-09-14
申请号：PCT/US2006/007955
申请日：2006-03-06
申请人： BIOGEN IDEC MA INC. , LUGOVSKOY, Alexey, Alexandrovich , HANF, Karl , LI, You , SIMON, Kenneth , VAN VLIJMEN, Herman
发明人： LUGOVSKOY, Alexey, Alexandrovich , HANF, Karl , LI, You , SIMON, Kenneth , VAN VLIJMEN, Herman
CPC分类号： C07K1/00 , C07K16/00 , C07K16/2842 , C07K16/30 , C07K16/465 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/92
摘要： The present invention is based, at least in part, on the discovery that strategic modifications of non-human donor antibody CDR residue(s) can be used to humanize antibodies. Such modifications modulate the 3D structural fit between donor antibody CDRs and human acceptor antibody framework regions that comprise the variable domains of a CDR-grafted antibody. Whereas prior art methods of humanization have relied on making framework substitutions (in which selected human framework residues are backmutated to the corresponding amino acid residue present in the non-human donor antibody), the instant invention is based, at least in part, on a method of humanizing antibodies in which selected CDR residues, and optionally adjacent FR residues, are changed in order to accommodate differences in FR amino acid sequences between donor and acceptor antibodies.
摘要翻译：本发明至少部分地基于以下发现，即可以使用非人供体抗体CDR残基的战略修饰来使抗体人源化。这样的修饰调节供体抗体CDR和包含CDR移植抗体的可变结构域的人受体抗体框架区之间的3D结构拟合。而现有技术的人源化方法依赖于进行框架取代（其中所选择的人类框架残基反向到存在于非人供体抗体中的相应氨基酸残基），本发明至少部分地基于人源化抗体的方法，其中选择的CDR残基和任选相邻的FR残基被改变以适应供体和受体抗体之间的FR氨基酸序列的差异。

9. 发明申请

WO2004002431A2 HUMANIZED ANTI-LYMPHOTOYIN BETA RECEPTOR ANTIBODIES 审中-公开
标题翻译：人类抗-LYMPHOTOYINβ受体抗体
公开(公告)号：WO2004002431A2
公开(公告)日：2004-01-08
申请号：PCT/US2003/020762
申请日：2003-07-01
申请人： BIOGEN, INC. , GARBER, Ellen , SIMON, Kenneth , SALDANHA, Jose
发明人： GARBER, Ellen , SIMON, Kenneth , SALDANHA, Jose
IPC分类号： A61K
CPC分类号： C07K16/2875 , A61K2039/505 , C07K2317/24 , C07K2317/565
摘要： This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the use of the antibodies alone or in combination with chemotherapeutic agent(s) in therapeutic methods.
摘要翻译：本发明涉及针对淋巴毒素β受体（LT-β-R）特异性的人源化抗体，产生这些抗体的细胞系，由抗体制备的免疫化学物质，以及使用该抗体的诊断方法。本发明还涉及在治疗方法中单独或与化学治疗剂组合使用抗体。

10. 发明申请

WO2003100033A3 ANTI-αvβ6 ANTIBODIES 审中-公开
公开(公告)号：WO2003100033A3
公开(公告)日：2003-12-04
申请号：PCT/US2003/008048
申请日：2003-03-13
申请人： BIOGEN, INC. , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , VIOLETTE, Shelia, M. , WEINREB, Paul, H. , SIMON, Kenneth, J. , SHEPPARD, Dean , LEONE, Diane, R.
发明人： VIOLETTE, Shelia, M. , WEINREB, Paul, H. , SIMON, Kenneth, J. , SHEPPARD, Dean , LEONE, Diane, R.
IPC分类号： A61K39/395
摘要： Monoclonal antibodies that specifically bind to α v β 6 . Also included are methods of using these antibodies to treat mammals having or at risk of having α v β 6 -mediated diseases, or to diagnose α v β 6 -mediated diseases.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式